Pharmafile Logo

Symtuza

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Trial data suggest Abivax’ drug may clear latent HIV

The drug reduced HIV DNA in cells over 28 days

- PMLiVE

90TEN celebrates double win for HIV campaign at Communiqué 2018

Agency wins two awards for bold My Journey: Flight HIV101 campaign

Gilead Sciences

Gilead’s Biktarvy gets European approval, setting up battle with GSK

The drug could offset Gilead's disappointing hep C franchise

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links